Less Than Half Take Home Bowel Cancer Test Despite High Awareness, Australia
6/08/2011
New Cancer Council research released today (8/6) shows although more than 80% of people aged 50+ are aware of a simple, at-home screening test for bowel cancer, less than half of those aware of FOBT have actually done the test. The research, conducted in Victoria, also found that most respondents (75%) could not recall their GP ever mentioning the faecal occult blood test (FOBT) to them...
Drug Shows Promise In Prostate Cancer Spread To Bone
6/08/2011
A new drug to treat prostate cancer shows early promise, particularly against tumors that have spread to the bone, a multi-site study shows. The drug Cabozantinib is designed to target mainly two important pathways linked to the growth and spread of prostate cancer. The drug had the most effect on tumors that had spread to the bone...
UT Southwestern Research Uncovers Genetic Link Between Emphysema, Lung Cancer
6/08/2011
A gene linked to emphysema also can be a factor for developing lung cancer unrelated to cigarette smoking, UT Southwestern Medical Center research indicates. Smoking was the only known risk factor previously associated with both diseases...
New Campaign Asks Parents To Be Brain Tumour Aware
6/07/2011
A new campaign is being launched to help parents and health professionals spot the signs of brain tumours in children and young people. HeadSmart aims to speed up diagnosis rates and raise awareness of brain tumour symptoms. Louise Pennell visited the doctor several times with her four year old son, Tom before he was diagnosed with a brain tumour...
J&J's Zytiga Extends Life; Other Prostate Cancer Alternatives?
6/07/2011
Zytiga (abiraterone acetate), an ingested pill treatment manufactured by J&J, has been found to potentially extend life by up to four months in men with spreading cancer who have already been treated with chemotherapy. However, there are other altervatives if so desired...
Nuvilex, Inc. Readies Pancreatic Cancer Treatment For Expanded Phase II Clinical Trials
6/07/2011
Nuvilex, Inc. (OTCQB: NVLX) announced today it is aggressively engaging the steps necessary to use its encapsulated cell technology for pancreatic cancer in expanded Phase II clinical trials in the United States, Europe and Australia. The Company's objective is to have a protocol submitted to the regulatory agencies in these countries as quickly as possible...
Investigators Report Full Phase 3 Lymphoseek (Tilmanocept) Study Results At ASCO
6/07/2011
Independent investigators reported today full results from the NEO3-09 study, reaffirming earlier top-line results that showed Lymphoseek® (99mTc-tilmanocept) met all primary and secondary endpoints and exhibited superior performance to vital blue dye in intraoperative lymphatic mapping (ILM) procedures...
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that lipegfilgrastim (INN; internal code - XM22) achieved its primary endpoint of reducing the duration of severe neutropenia in a Phase III study designed to evaluate the efficacy and safety of lipegfilgrastim (XM22) compared to pegfilgrastim (Amgen's Neulasta™)...
Adolor Corporation Completes Enrollment In Phase 2 OIC Program
6/07/2011
Adolor Corporation (NasdaqGM: ADLR) today announced that it has completed enrollment in its Phase 2 clinical evaluation of ADL5945 in chronic, non-cancer pain patients with opioid-induced constipation (OIC). Adolor is conducting two Phase 2 studies of ADL5945 in OIC patients in parallel. The first study is evaluating two doses of ADL5945 - 0.10 mg and 0...
Merck (NYSE:MRK), known outside the United States and Canada as MSD, and ARIAD Pharmaceuticals, Inc., (NASDAQ:ARIA), today announced the presentation of detailed results from the Phase III SUCCEED clinical trial. SUCCEED evaluated oral ridaforolimus, an investigational mTOR inhibitor, in patients with metastatic soft-tissue or bone sarcomas who previously had a favorable response to chemotherapy...